Taken together, these studies indicate that therapies aimed at targeting the accumulation and/or proliferation of TAMs may improve clinical outcomes for breast cancer patients, and as a result CSF-1R inhibitors and blocking antibodies have entered clinical trials for various cancer types, including breast cancer. This evidence concerns the gene CSF1R and breast cancer.